The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin

Accumulation of oxidatively modified low-density lipoprotein (oxLDL) in the vascular wall is a characteristic feature of atherosclerosis. oxLDL can be taken up into monocytes, smooth muscle cells, and endothelial cells by sev eral known scavenger receptors such as scavenger receptor class A I and II, CD36, and CD68. A new lectin like oxLDL receptor (LOX-1) was recently foun d in bovine and human endothelial cells. We studied whether LOX-1 is also e xpressed in other cells present in the atherosclerotic lesion and whether i ts expression can be modified. We found LOX-1 expression in human blood mon ocytes, umbilical smooth muscle and endothelial cells, and 3T3 fibroblasts. LOX-1 mRNA expression in monocytes could be significantly suppressed by lo vastatin. Thus, LOX-1 expression is not restricted to endothelial cells and its down-regulation by HMG-CoA reductase inhibitors could contribute to th e clinical benefits of these drugs. (C) 1999 Elsevier Science Inc.